Affiliation:
1. Bayer HealthCare Pharmaceuticals; Wuppertal; Germany
Subject
Pharmacology (medical),Pharmacology
Reference41 articles.
1. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor;Perzborn;J Thromb Haemost,2005
2. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct Factor Xa inhibitor rivaroxaban;Gerotziafas;J Thromb Haemost,2007
3. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor;Biemond;Thromb Haemost,2007
4. Antithrombotic efficacy of BAY 59-7939 - an oral, direct Factor Xa inhibitor - compared with fondaparinux in animal arterial thrombosis and thromboembolic death models;Perzborn;Eur Heart J,2005
5. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies;Turpie;Thromb Haemost,2011
Cited by
315 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献